TR-1 notification of major interest in shares

The notification can be found here.

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

Confirmation of share cancellation - Total voting rights

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed medical diagnostics business, refers to its announcement dated 3 October 2017 (the "Previous Announcement") and confirms that with effect from 22 December 2017 it will cancel 78,113 of the 205,561 Compensation Shares (as defined in the Previous Announcement (the "Cancellation").

Total voting rights

As at 30 November 2017, the Company's total issued share capital consists of 457,632,749 ordinary shares of 1 pence each ("Ordinary Shares") with one voting right per share. The Company holds no Ordinary Shares in treasury.

TR-1: Standard form for notification of major holdings

Standard form for notification of major holdings

Confirmation of share cancellation

EKF Diagnostics Holdings plc confirms that the 6,630,032 will be cancelled.

Total voting rights

As at 31 October 2017, the Company's total issued share capital consists of 458,632,749 ordinary shares of 1 pence each ("Ordinary Shares") with one voting right per share. The Company holds 1,000,000 Ordinary Shares in treasury.